FDA Approves First Gene Therapy for Genetic Hearing Loss

The FDA has approved Regeneron's Otarmeni, marking the first gene therapy available for genetic hearing loss. This approval represents a major medical milestone offering hope to patients with rare forms of deafness. The technology opens new avenues for treating previously incurable conditions, signaling a shift in how medical science approaches genetic disorders.